NCT05940883 - A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

November 21, 2023

Study Completion Date

December 5, 2023

Conditions

Healthy

Interventions

DRUG

Y-2 Sublingual Tablet

Subjects will receive one Y-2 sublingual tablet sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.

DRUG

Y-2 Sublingual Tablet

Subjects will receive two Y-2 sublingual tablets sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.

DRUG

Y-2 Sublingual Tablet

Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition A, Day 6 with condition B and Day 11 with condition C.

DRUG

Y-2 Sublingual Tablet

Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition B, Day 6 with condition C and Day 11 with condition A.

DRUG

Y-2 Sublingual Tablet

Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition C, Day 6 with condition A and Day 11 with condition B.

DRUG

Placebo

Placebo, sublingually, single and multiple ascending dosing in group 1 and 2 subjects.

Trial Locations (1)

91206

Parexel International Los Angeles Early Phase Clinical Unit, Glendale

All Listed Sponsors

lead

Simcere Pharmaceutical Co., Ltd

OTHER